Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415387 · ClinicalTrials.gov registry record · Early Phase 1
Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
A Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 172
- Enrollment target
NCT02415387 is a Early Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 172 participants.
The verdict
NCT02415387, a Early Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness levels affect how their bodies handle a challenge to their immune system. A vaccine is a substance or group of substances meant to cause the immune system to respond to a tumor or to microorganisms such as bacteria or viruses. Immune responses may cause excess inflammation in the body and behavioral changes, such as depression, fatigue, pain, and problems with thinking and reasoning. Studying immune responses in patients with breast cancer who have undergone primary cancer treatment may help doctors learn whether physical fitness can protect the body from effects of immune system stress and whether it may be able to reduce health problems in patients with breast cancer.
Interventions
- OTHER Placebo
- BIOLOGICAL typhoid vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2021-04-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415387
The ClinicalTrials.gov registry entry for NCT02415387 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02415387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415387 about?
NCT02415387 is a clinical study titled "Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer". This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness levels affect how their bodies handle a challenge to their immune system. A ...
What is the current status of trial NCT02415387?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 172 participants. The study started on 2014-01-01. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT02415387?
The interventions under investigation include: Placebo (OTHER), typhoid vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02415387?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.